ArticleBiomaterials research2025
Investigating the Mechanism of Qifenggubiao Granules in COPD Treatment: An Integrated Exploration of Ferroptosis and the Gut-Lung Axis.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Gut-Skin Axis in Atopic Dermatitis and Inflammatory Bowel Disease: Mechanisms, Microbiota, and Therapeutic Implications.Journal of personalized medicine · 2026Review
- Exploring Ferroptosis: A Key Mechanism in Respiratory System Diseases and its Therapeutic Potential.Applied biochemistry and biotechnology · 2026Review
- Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The gut-lung axis: a new perspective on the impact of atmospheric particulate matter exposure on chronic obstructive pulmonary disease.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although an increasing number of studies focus on treating chronic obstructive pulmonary disease (COPD) through the gut-lung axis and immunomodulation, its underlying mechanisms remain poorly understood. Previous research has shown that Qifenggubiao granules (QFGB) exhibit obvious clinical efficacy in treating allergic rhinitis and chronic cough, demonstrating excellent antioxidant and anti-inflammatory properties. However, whether it can alleviate COPD by inhibiting ferroptosis remains unclear. Additionally, its immunomodulatory mechanisms in gut microbiota dysbiosis-related inflammation require further investigation. In this study, we found that QFGB not only suppresses oxidative stress but also inhibits ferroptosis by reducing lipid peroxide levels and increasing the expression of glutathione peroxidase 4 and xCT. The authors also discovered that QFGB significantly alleviates pulmonary dysfunction in COPD animal models by regulating macrophage polarization and remodeling the inflammatory immune microenvironment, thereby suppressing inflammation. Furthermore, 16
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.